CJEU ‘shuts door’ on SPCs for second medical uses
Kymab victorious before UK Supreme Court in Regeneron appeal
UKIPO cancels SPC extension at owner’s request
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity